Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy

Journal of the Peripheral Nervous System

Volumn 20, Issue 4, 2015, Pages 363-371

  Polydefkis, Michael ^a   Arezzo, Joseph ^b   Nash, Marshall ^c   Bril, Vera ^d   Shaibani, Aziz ^e   Gordon, Robert J ^f   Bradshaw, Kate L ^f   Junor, Roderick W J ^f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c NeuroStudiesnet   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e Nerve and Muscle Center of Texas   (United States)

^f EISAI CO LTD   (Japan)

Author keywords

aldose reductase; clinical trial; diabetic neuropathy; neuropathy progression

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; PLACEBO; RANIRESTAT; PYRAZINE DERIVATIVE; SPIRO COMPOUND;

ADULT; AGED; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; BACKACHE; CATARACT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEPRESSION; DIABETES CONTROL; DIABETIC NEUROPATHY; DIABETIC SENSORIMOTOR POLYNEUROPATHY; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; GASTROENTERITIS; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MOTOR NERVE CONDUCTION; MUSCULOSKELETAL PAIN; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PERIPHERAL EDEMA; PERONEUS NERVE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SENSORIMOTOR NEUROPATHY; SYMPTOM; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; DIABETIC NEUROPATHIES; DISEASE COURSE; DRUG EFFECTS; MIDDLE AGED; NERVE CONDUCTION; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYNEUROPATHIES; TREATMENT OUTCOME;

AGED; DIABETIC NEUROPATHIES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURAL CONDUCTION; POLYNEUROPATHIES; PYRAZINES; QUALITY OF LIFE; SPIRO COMPOUNDS; TREATMENT OUTCOME;

EID: 84959537888     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/jns.12138     Document Type: Article

References (24)

1. Bastyr EJ 3rd, Price KL, Bril V, Group MS (2005). Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clin Ther 27: 1278-1294.
2. Bril V, Buchanan RA, (2004). Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care 27: 2369-2375.
3. Bril V, Buchanan RA, (2006). Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 29: 68-72.
4. Bril V, Hirose T, Tomioka S, Buchanan R, Ranirestat Study G (2009). Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care 32: 1256-1260.
5. Carrington AL, Shaw JE, Van Schie CH, Abbott CA, Vileikyte L, Boulton AJ, (2002). Can motor nerve conduction velocity predict foot problems in diabetic subjects over a 6-year outcome period? Diabetes Care 25: 2010-2015.
6. Davis TM, Yeap BB, Davis WA, Bruce DG, (2008). Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 51: 562-566.
7. Diabetes Control Complications Trial (DCCT) Research Group (1995). Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 38: 869-880.
8. Dunnett CW, (1955). A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 50: 1096-1121.
9. Dunnett CW, (1964). New tables for multiple comparisons with a control. Biometrics 20: 482-491.
10. Dyck PJ, O'Brien PC, (1989). Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of diabetic neuropathy. Diabetes Care 12: 649-652.
11. Dyck PJ, Davies JL, Litchy WJ, O'Brien PC, (1997). Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 49: 229-239.
12. England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT, Cohen JA, Fisher MA, Howard JF, Kinsella LJ, Latov N, Lewis RA, Low PA, Sumner AJ, American Academy of N, American Association of Electrodiagnostic M, American Academy of Physical M, Rehabilitation (2005). Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 64: 199-207.
13. Gibbons CH, Freeman R, Tecilazich F, Dinh T, Lyons TE, Gnardellis C, Veves A, (2013). The evolving natural history of neurophysiologic function in patients with well-controlled diabetes. J. Peripher. Nerv. Syst. 18: 153-161.
14. Greene DA, Sima AA, Stevens MJ, Feldman EL, Lattimer SA, (1992). Complications: neuropathy, pathogenetic considerations. Diabetes Care 15: 1902-1925.
15. Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W, Boulton AJ, (1998). Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 352: 1978-1981.
16. Oates PJ, (2008). Aldose reductase, still a compelling target for diabetic neuropathy. Curr Drug Targets 9: 14-36.
17. Ota A, Kakehashi A, Toyoda F, Kinoshita N, Shinmura M, Takano H, Obata H, Matsumoto T, Tsuji J, Dobashi Y, Fujimoto WY, Kawakami M, Kanazawa Y, (2013). Effects of long-term treatment with ranirestat, a potent aldose reductase inhibitor, on diabetic cataract and neuropathy in spontaneously diabetic torii rats. J Diabetes Res 2013: 175901.
18. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M, (1995). Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333: 89-94.
19. Polydefkis M, Hauer P, Sheth S, Sirdofsky M, Griffin JW, McArthur JC, (2004). The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain 127: 1606-1615.
20. Stavniichuk R, Shevalye H, Hirooka H, Nadler JL, Obrosova IG, (2012). Interplay of sorbitol pathway of glucose metabolism, 12/15-lipoxygenase, and mitogen-activated protein kinases in the pathogenesis of diabetic peripheral neuropathy. Biochem Pharmacol 83: 932-940.
21. Tesfaye S, Tandan R, Bastyr EJ 3rd, Kles KA, Skljarevski V, Price KL, Ruboxistaurin Study G (2007). Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trials. Diabetes Care 30: 2626-2632.
22. Van Acker K, Bouhassira D, De Bacquer D, Weiss S, Matthys K, Raemen H, Mathieu C, Colin IM, (2009). Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 35: 206-213.
23. Vinik AI, Strotmeyer ES, Nakave AA, Patel CV, (2008). Diabetic neuropathy in older adults. Clin Geriatr Med 24: 407-435, v.
24. Ziegler D, Low PA, Litchy WJ, Boulton AJ, Vinik AI, Freeman R, Samigullin R, Tritschler H, Munzel U, Maus J, Schutte K, Dyck PJ, (2011). Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 34: 2054-2060.